Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Name: Kaimen Rigor review — Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Item: Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Rating: 92
Author: Alpha1

Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, Özgüroğlu M, Pereira de Santana Gomes AJ, Vianna K, Luo H, Gotto GT, Cheng HH, Kim W, Varela CR, Schaeffer D, Kramer K, Li S, Baron B, Shen F, Mundle SD, McCarthy SA, Olmos D, Chi KN, Rathkopf DE.

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 4.5★ (Strong), 0 critical, 5 high issues for “Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Read alongside

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Read full text (PMC)

DOI

10.1038/s41591-025-03961-8

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/a8ba244b-e813-414e-ae76-0e1b1e786ab2" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/a8ba244b-e813-414e-ae76-0e1b1e786ab2/badge" alt="Kaimen Rigor review — 4.5★ (Strong), 0 critical, 5 high issues for “Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

e94de48d3854ca867fac4ed52900b170466682c3bf7c8dbf1bde94b36ee88c70

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Paper source

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

4.5 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsOverstated claim−0.5★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Biggest issues

01Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
This is the first demonstration of efficacy of a PARP inhibitor in mCSPC.
“In conclusion, this is, to our knowledge, the first demonstration of efficacy of a PARP inhibitor in mCSPC.”
DiscussionFind in source

Findings by category

01ArithmeticNone found 202OverreachOverstated conclusions · partly checked 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 106CopyeditCopyediting

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper presents a well-designed phase 3 trial with strong scientific premise, rigorous design, and transparent reporting. Three rigor dimensions receive warnings: ethical approvals lack a named IRB/protocol number, key resources lack manufacturer information for the investigational drugs, and statistical analysis uses imprecise p-value thresholds. Data sharing is managed via YODA but genomic data are not deposited in a public repository. Copyedit issues are minor, but one claim is overstated.

Three independent reviewer runs from the same model were synthesized; they diverged on ethical approvals, key resources, statistical analysis, and data code availability, and the consensus was reached by weighing the combined evidence. The statistics verification checked 10 values and found all consistent; the remaining analyses were not verified. The citation check found no retracted or missing references. The claim audit identified one overstated claim.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 10 tests: 10 consistent, 0 inconsistent; 4 recomputed directly from the reported test statistics, 6 via agent-written checks.

Overstated conclusions

2 findings · worst medium

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

12 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior research on HRR alterations in prostate cancer, PARP inhibitor efficacy in mCRPC, and the rationale for combining PARP and androgen receptor pathway inhibition. The hypothesis follows logically: PARP inhibition within 6 months of starting androgen deprivation therapy for mCSPC could improve radiographic progression-free survival. Limitations of prior work (e.g., resistance to PARP monotherapy, heterogeneity of HRR subgroups) are acknowledged and the design addresses them by testing earlier in the disease course.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific rationale from prior evidence on PARP inhibition in mCRPC and the rationale for testing in mCSPC, with a well-formulated hypothesis.

Evidence

“We hypothesized that PARP inhibition within 6 months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) could be effective and improve radiographic progression-free survival when added to standard-of-care treatments.”

AbstractFind in source

“We therefore aimed to evaluate whether the combination of PARP inhibition and an androgen receptor pathway inhibitor at response to first-line androgen deprivation (castration-sensitive prostate cancer) would be effective.”

IntroductionFind in source

paraphrase[Introduction, paragraph 2]

“Despite the efficacy ... resistance commonly occurs, often after emergence of secondary alterations in BRCA2 that restore HRR function.”

PASSReviewer 2· 95% conf

The premise is well established with extensive citation of prior work on PARP inhibition, HRR gene alterations, and prior mCSPC/mCRPC trials, and a clear rationale links it to the study objectives.

Evidence

paraphrase[Introduction, paragraph 1]

“Deleterious germline or somatic alterations in HRR genes are associated with poor prognosis and occur in up to 25% of patients, with BRCA2 being the most commonly altered.”

Introduction ¶2Find in source

paraphrase[Introduction, paragraph 1]

“Despite the efficacy (improvements in both radiographic progression-free survival and overall survival) reported for PARP inhibitor monotherapy in mCRPC, resistance commonly occurs, often after emergence of secondary alterations in BRCA2 that restore HRR function.”

PASSReviewer 3· 95% conf

The paper establishes a strong scientific foundation, citing prior studies on PARP inhibition in prostate cancer, HRR alterations, and the rationale for earlier intervention.

Evidence

paraphrase[Introduction]

“Although most clinical studies confirm BRCA1/BRCA2 loss cancers as sensitive, other genes biologically involved in HRR have been included in clinical trials for metastatic prostate cancer relapsing after castration... with variable levels of efficacy.”

IntroductionFind in source

paraphrase[Introduction]

“Despite the efficacy... reported for PARP inhibitor monotherapy in mCRPC, resistance commonly occurs, often after emergence of secondary alterations in BRCA2 that restore HRR function.”

Randomization method (permuted block via interactive web randomization system) and unit (patient) are stated. Double-blinding is described, with unblinding allowed only after confirmed progression. The power analysis is detailed (91% power for HR 0.64). Eligibility criteria are extensive. ITT analysis and a data-as-observed approach for missing data are defined. Replicate, controls, and independent replication are n/a for a human RCT.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Design is rigorous: randomized, double-blind, placebo-controlled with permuted-block randomization, prespecified power calculations, and clear eligibility criteria.

Evidence

“Randomization was done using permuted block randomization managed via an interactive web randomization system.”

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting